Loading
Alzheimer Disease / Disease Models, Animal · Journal article
Experimental Neurology · July 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study introduces a novel double transgenic mouse platform (5xFAD+/-/RosatdT) combined with retrograde viral tracing to selectively label and track degeneration of corticospinal neurons in Alzheimer's disease. The work demonstrates that hAPP accumulates in axons and synaptic terminals of labeled neurons alongside tdT expression, providing a secondary anatomical measure of neurodegeneration, but it is a tool-development study without therapeutic or clinical endpoints.
Preclinical transgenic mouse model development with retrograde viral labeling and immunohistochemistry. 5xFAD+/-/RosatdT double transgenic mice; no age, sex, or health status details provided beyond injection timing.. Intervention: Intra-spinal cord injection of AAV-retrograde/Cre at 2–4 months of age to retrogradely transduce and induce tdT expression in projection neurons.
Age-dependent accumulation of hAPP-positive granules in neuronal cell bodies, axons, and synaptic terminals tdT expressed by corticospinal neurons accumulated in the same granules as hAPP and other AD pathology markers Quantitative assessments confirmed age-related degeneration of layer V corticospinal neurons accompanied by progressive accumulation of tdT and hAPP-positive granule clusters
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a preclinical mechanistic study developing a novel transgenic tracking platform in mice, demonstrating proof-of-concept for labeling degenerating neurons but lacking clinical translation or therapeutic outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This paper describes a novel double transgenic-based platform developed by crossing a murine model of Alzheimer's disease (AD), 5xFAD mice with RosatdTomato (tdT) reporter mice, to track degeneration of specific populations of neurons. 5xFAD+/-/RosatdT mice received intra-spinal cord injections of AAV-retrograde (rg)/Cre at 2-4 months of age to retrogradely transduce and induce tdT expression by corticospinal neurons (CSNs) in layer V of the sensorimotor cortex as well as neurons in the red nucleus and reticular formation that project to the spinal cord. Brains and spinal cords were collected 2-3 weeks post-injection or between 6-10 and 11-15 months of age. Immunohistochemical studies of transgene expression throughout the brain and spinal cord using an antibody selective for human APP (hAPP) revealed age-dependent accumulation of clusters of hAPP-positive granules in areas containing hAPP-labeled neuronal cell bodies. Surprisingly, there were also hAPP-positive granules in regions containing axons and synaptic terminals from hAPP expressing neurons. Moreover, tdT expressed by CSNs accumulated in the same granules as hAPP, and both tdT and hAPP were present in clusters of granules with other markers of AD pathology. Quantitative assessments confirmed age-related degeneration of layer V CSNs accompanied by progressive accumulation of clusters of tdT and hAPP-positive granules. Overall, our results indicate that accumulation of aggregated hAPP in areas containing axons and synaptic terminals from hAPP expressing neurons is a prominent feature of AD pathophysiology in 5xFAD mice and that accumulation of clusters of hAPP granules provides a secondary measure to track neurodegeneration of identified populations of genetically labeled neurons.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.